These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6806235)

  • 1. Penetration of SQ 26,776, a new monobactam antibiotic, into Escherichia coli and Pseudomonas aeruginosa.
    Russell AD; Furr JR
    J Antimicrob Chemother; 1982 Apr; 9(4):329-31. PubMed ID: 6806235
    [No Abstract]   [Full Text] [Related]  

  • 2. Growth curve patterns of Escherichia coli and Pseudomonas aeruginosa submitted to different SQ 26,776 concentrations.
    Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():89-96. PubMed ID: 6799486
    [No Abstract]   [Full Text] [Related]  

  • 3. In-vitro studies on SQ 26,776, a new monobactam antibiotic.
    Russell AD
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():81-8. PubMed ID: 6799485
    [No Abstract]   [Full Text] [Related]  

  • 4. In-vitro activity of the monobactam Ro 17-2301 against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Bremner DA
    J Antimicrob Chemother; 1985 Oct; 16(4):457-61. PubMed ID: 3934129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of the monobactam SQ 26,776 against antibiotic resistant enterobacteria, including Serratia spp.
    Reeves DS; Bywater MJ; Holt HA
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():57-68. PubMed ID: 6799483
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects.
    Swabb EA; Leitz MA; Pilkiewicz FG; Sugerman AA
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():131-40. PubMed ID: 7199041
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolation and characterization of lividomycin A inactivated by Pseudomonas aeruginosa and Escherichia coli carrying R factor.
    Kondo S; Yamamoto H; Naganawa H; Umezawa H
    J Antibiot (Tokyo); 1972 Aug; 25(8):483-4. PubMed ID: 4630725
    [No Abstract]   [Full Text] [Related]  

  • 8. Penetration through the gram-negative cell wall: a co-determinant of the efficacy of beta-lactam antibiotics.
    Zimmermann W
    Int J Clin Pharmacol Biopharm; 1979 Mar; 17(3):131-4. PubMed ID: 107128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases.
    Livermore DM; Williams JD
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():29-37. PubMed ID: 6799480
    [No Abstract]   [Full Text] [Related]  

  • 10. In-vitro activity of monobactam, SQ 26,776, against Gram-negative bacteria.
    Percival A; Thomas E; Hart CA; Karayiannis P
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():49-55. PubMed ID: 6799482
    [No Abstract]   [Full Text] [Related]  

  • 11. Review of single- and multiple-dose pharmacokinetics of the monobactam, aztreonam (SQ 26,776) in healthy subjects.
    Swabb EA; Sugerman AA
    Chemotherapy; 1983; 29(5):313-21. PubMed ID: 6684541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in-vitro activity of SQ 82,291, a new monobactam, in comparison with aztreonam.
    García-Rodríguez JA; García-Sánchez JE; Plata A; Trujillano I
    J Antimicrob Chemother; 1986 Mar; 17(3):303-7. PubMed ID: 3754552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The problems in the outer membrane permeability and the antibiotic resistance of Pseudomonas aeruginosa.
    Nakae T
    Kitasato Arch Exp Med; 1991 Sep; 64(2-3):115-21. PubMed ID: 1667326
    [No Abstract]   [Full Text] [Related]  

  • 14. [In vitro activity of Ro 17-2301, a new monobactam antibiotic].
    Roy C; Foz A; Segura C; Tirado M; Teixell M
    Med Clin (Barc); 1985 Jun; 85(5):183-6. PubMed ID: 3927089
    [No Abstract]   [Full Text] [Related]  

  • 15. [Susceptibility of Pseudomonas aeruginosa to aztreonam in comparison to other pseudomonas-active beta-lactam antibiotics and gentamicin].
    Wundt W; Lange KP; Baumgärtner M
    Arzneimittelforschung; 1985; 35(8):1322-5. PubMed ID: 3935123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanism-based GlcNAc-inspired cyclophellitol inactivator of the peptidoglycan recycling enzyme NagZ reverses resistance to β-lactams in Pseudomonas aeruginosa.
    Ho LA; Winogrodzki JL; Debowski AW; Madden Z; Vocadlo DJ; Mark BL; Stubbs KA
    Chem Commun (Camb); 2018 Sep; 54(75):10630-10633. PubMed ID: 30178799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity of carumonam for penicillin-binding proteins.
    Then RL; Kohl I
    Chemotherapy; 1985; 31(4):246-54. PubMed ID: 3928279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo functional and molecular characterization of the Penicillin-Binding Protein 4 (DacB) of Pseudomonas aeruginosa.
    Aguilera Rossi CG; Gómez-Puertas P; Ayala Serrano JA
    BMC Microbiol; 2016 Oct; 16(1):234. PubMed ID: 27716106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic uptake: unusual results for unusual molecules.
    Hancock RE; Bellido F
    J Antimicrob Chemother; 1992 Mar; 29(3):235-9. PubMed ID: 1592694
    [No Abstract]   [Full Text] [Related]  

  • 20. RND efflux pump mediated antibiotic resistance in Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa: a major issue worldwide.
    Puzari M; Chetia P
    World J Microbiol Biotechnol; 2017 Feb; 33(2):24. PubMed ID: 28044273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.